KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $4.9 billion.

  • Quest Diagnostics' Treasury Shares rose 346.58% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year increase of 346.58%. This contributed to the annual value of $4.9 billion for FY2024, which is 64.24% up from last year.
  • Latest data reveals that Quest Diagnostics reported Treasury Shares of $51.0 million as of Q3 2025.
  • Quest Diagnostics' 5-year Treasury Shares high stood at $95.0 million for Q2 2021, and its period low was $1.0 million during Q4 2021.
  • Moreover, its 5-year median value for Treasury Shares was $50.0 million (2023), whereas its average is $48.2 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first crashed by 4446.81% in 2021, then soared by 4902.3% in 2022.
  • Quarter analysis of 5 years shows Quest Diagnostics' Treasury Shares stood at $3.5 billion in 2021, then surged by 35.33% to $4.7 billion in 2022, then grew by 3.27% to $4.8 billion in 2023, then rose by 0.64% to $4.9 billion in 2024, then grew by 0.8% to $4.9 billion in 2025.
  • Its last three reported values are $4.9 billion in Q3 2025, $4.8 billion for Q2 2025, and $4.8 billion during Q1 2025.